Menu
Search
|

Menu

Close
X

Alexion Pharmaceuticals Inc ALXN.OQ (NASDAQ Stock Exchange Global Select Market)

118.93 USD
+4.34 (+3.79%)
As of Feb 23
chart
Previous Close 114.59
Open 115.78
Volume 726,328
3m Avg Volume 719,997
Today’s High 118.99
Today’s Low 114.55
52 Week High 149.17
52 Week Low 96.18
Shares Outstanding (mil) 221.68
Market Capitalization (mil) 26,364.57
Forward P/E 54.74
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 21 analysts

KEY STATS

Revenue (mm, USD)
FY17
3,551
FY16
3,084
FY15
2,604
EPS (USD)
FY17
2.173
FY16
1.738
FY15
0.764
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
54.74
33.62
Price to Sales (TTM)
vs sector
7.42
8.35
Price to Book (MRQ)
vs sector
2.97
5.22
Price to Cash Flow (TTM)
vs sector
26.74
25.88
Total Debt to Equity (MRQ)
vs sector
36.33
15.84
LT Debt to Equity (MRQ)
vs sector
34.45
12.39
Return on Investment (TTM)
vs sector
3.90
13.63
Return on Equity (TTM)
vs sector
5.56
15.39

EXECUTIVE LEADERSHIP

David Brennan
Chairman of the Board, Since 2017
Salary: $230,769.00
Bonus: --
Ludwig Hantson
Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Paul Clancy
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
John Moriarty
Executive Vice President, General Counsel, Since 2014
Salary: $570,000.00
Bonus: --
Julie O'Neill
Executive Vice President - Global Operations, Since 2015
Salary: $509,023.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

100 College St
NEW HAVEN   CT   06510-3210

Phone: +1203.2722596

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

SPONSORED STORIES